Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00471003 |
The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Micardis (Telmisartan, BAY68-9291) |
Phase IV |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients |
Estimated Enrollment: | 6250 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Arm 1 |
Drug: Micardis (Telmisartan, BAY68-9291)
Primary care hypertensive patients starting the therapy with Telmisartan
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Primary care clinic
Inclusion Criteria:
Exclusion Criteria:
Contact: Bayer Clinical Trials Contact | clinical-trials-contact@bayerhealthcare.com |
Croatia | |
Recruiting | |
Many Locations, Croatia | |
Poland | |
Completed | |
Many Locations, Poland | |
Slovakia | |
Completed | |
Many Locations, Slovakia | |
Slovenia | |
Recruiting | |
Many Locations, Slovenia |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Sp. z o.o ( Medical Affairs Therapeutic Area Head ) |
Study ID Numbers: | 12729, KL0601PL, 13929 - KL0601SI, 12804 - KL0601SK, 14326 - KL0601HR |
Study First Received: | May 7, 2007 |
Last Updated: | April 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00471003 History of Changes |
Health Authority: | Poland: Medical Devices and Biocidal Products; Slovakia: State Institute for Drug Control; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Slovakia: State Institute for Drug Control; Croatia: Agency for Medicinal Product and Medical Devices; Croatia: Ethics Committee; Slovenia: Ethics Committee |
Hypertension |
Angiotensin II Type 1 Receptor Blockers Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Telmisartan |
Angiotensin II Protease Inhibitors Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors |
Cardiovascular Diseases Telmisartan Pharmacologic Actions Protease Inhibitors Hypertension |